Outcomes with as-needed ranibizumab after initial monthly therapy: Long-term outcomes of the phase III RIDE and RISE trials

Ophthalmology

Volumn 122, Issue 12, 2015, Pages 2504-2513.e1

  Boyer, David S ^a   Nguyen, Quan Dong ^b   Brown, David M ^c   Basu, Karen ^d   Ehrlich, Jason S ^d  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c RETINA CONSULTANTS OF HOUSTON   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTERIAL THROMBOEMBOLISM; ARTICLE; BRAIN HEMORRHAGE; CENTRAL FOVEAL THICKNESS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; SIDE EFFECT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETIC RETINOPATHY; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84947901120     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.08.006     Document Type: Article

References (13)

1. The Diabetic Retinopathy Clinical Research Network M.J. Elman, L.P. Aiello, R.W. Beck, and et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 117 2010 1064 1077 e35
2. Diabetic Retinopathy Clinical Research Network M.J. Elman, N.M. Bressler, H. Qin, and et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema Ophthalmology 118 2011 609 614
3. Q.D. Nguyen, D.M. Brown, D.M. Marcus, et al. on behalf of the RISE and RIDE Research Group Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
4. D.M. Brown, Q.D. Nguyen, D.M. Marcus, et al. on behalf of the RIDE and RISE Research Group Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE Ophthalmology 120 2013 2013 2022
5. Q.D. Nguyen, S.M. Shah, J.S. Heier, and et al. READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 116 2009 2175 2181 e1
6. Q.D. Nguyen, S.M. Shah, A.A. Khwaja, and et al. READ-2 Study Group. Two-year outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study Ophthalmology 117 2010 2146 2151
7. P. Massin, F. Bandello, J.G. Garweg, and et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study Diabetes Care 33 2010 2399 2405
8. P. Mitchell, F. Bandello, U. Schmidt-Erfurth, et al. on behalf of the RESTORE Study Group The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
9. M.S. Ip, A. Domalpally, J.J. Hopkins, and et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression Arch Ophthalmol 130 2012 1145 1152
10. G.E. Lang, A. Berta, B.M. Eldem, and et al. RESTORE Extension Study Group. Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: interim analysis of the RESTORE extension study Ophthalmology 120 2013 2004 2012
11. U. Schmidt-Erfurth, G.E. Lang, F.G. Holz, et al. on behalf of the RESTORE Extension Study Group Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study Ophthalmology 121 2014 1045 1053
12. M.S. Ip, A. Domalpally, J.K. Sun, and J.S. Ehrlich Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy Ophthalmology 122 2015 367 374
13. M.J. Elman, A. Ayala, N.M. Bressler, et al. for the Diabetic Retinopathy Clinical Research Group Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results Ophthalmology 122 2015 375 381